Patents Examined by Hankyel T. Park
  • Replication defective HIV vaccine
    Patent number: 6500623
    Abstract: A replication-defective HIV particle pseudotyped with vesicular stomatitis virus G protein (VSV-G). The pol gene of the HIV genome in the particle is modified to inactivate the pol reverse transcriptase and protcase activity. This pseudotyped HIV particle can infect many cell types, including human and simian cells, and only undergoes one round of replication. Furthermore, a virus-specific immune response can be detected in mice immunized with the VSV-G pseudotyped replication-defective HIV.
    Type: Grant
    Filed: November 9, 2000
    Date of Patent: December 31, 2002
    Assignee: Genecure LLP
    Inventor: Frank Yao Tsung Tung
  • Inviable virus particles as scaffolds for constructing flexible detection systems
    Patent number: 6500611
    Abstract: An innovative detection system for detecting small numbers of target analytes is disclosed. This system provides a novel method for attaching multiple copies of reporter groups to a single site on an analyte of interest. This system preferably comprises a virus capsid enclosing multiple detectable reporter groups, and a linking molecule which is capable of linking the capsid to the analyte of interest.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: December 31, 2002
    Inventor: Thomas L. Mattson
  • Methods of treatment of disease using adsorbent carriers
    Patent number: 6498007
    Abstract: The invention relates to a method for the removal of leucocytes from blood which comprises bringing blood that comprises infected leucocytes into contact with an adsorbent carrier that has a greater affinity for infected, activated and/or defective leucocytes than for uninfected leucocytes especially cellulose acetate. The method can be used in the apheresis treatment of diseases caused by pathogenic organisms, for example, HIV, HCV or malaria. It is especially useful for treatment of HIV.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: December 24, 2002
    Assignee: Japan Immunoresearch Laboratories Co., Ltd.
    Inventors: Masakazu Adachi, Toshifumi Hibi
  • Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy
    Patent number: 6498006
    Abstract: Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: December 24, 2002
    Assignee: Johnson T. Wong
    Inventor: Johnson T. Wong
  • Induction of a Th1-like response in vitro
    Patent number: 6495347
    Abstract: The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: December 17, 2002
    Assignee: Stressgen Biotechnologies Corporation
    Inventors: Marvin Siegel, N. Randall Chu, Lee A. Mizzen
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 6495332
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: December 17, 2002
    Assignees: The Sripps Research Institute, The Rockefeller University
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Retrovirus isolated from humans
    Patent number: 6492165
    Abstract: The present invention comprises spumavirus isolated from humans. More specifically, the spumavirus of the present invention was isolated from humans who had exposure to nonhuman primates. Importantly, the spumavirus of the present invention or antibodies to the spumavirus can be used to detect the presence of spumavirus or antibodies in body fluids, for pathogenicity studies of related viruses, and as a vector for gene therapies. The spumavirus of the invention can also be used for treatment of conditions in humans due to the presence of rapidly dividing cells and for recombinant live virus vaccination.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: December 10, 2002
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Margaret E. Callahan, Thomas M. Folks, Paul Sandstrom, Shambavi Subbarao, Jennifer Brown, Walid Heneine, William M. Switzer
  • Drug screen targeting lipoprotein-membrane anchorage
    Patent number: 6492128
    Abstract: A drug screening assay for identifying compounds for their potential effects on the long chain fatty acid dependant intracellular membrane anchorage sites of lipoproteins. Membranes-anchoring-target are incubated in the presence of the compound to be tested and the proportion of the target that is released by the compound is detected and quantitated. The benchmark for this assay are the prenylated proteins such as the farnesylated and palmitoylated oncogenic ras trigger proteins which are displaced from their anchorage at the intracellular plasma membrane by derivatives of Farnesyl Thiosalicylic Acid (FTS). The assay is adaptable to flexibly assay a large variety of anchored targets using a wide range of labeling and detection techniques in test wells, tissue culture, and in animals as injected cells or transgenic, thereby directly addressing a wide range of pharmacologically relevant needs.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: December 10, 2002
    Assignee: Ramot University Authority for Applied Research & Industrial Development, Ltd.
    Inventors: Roni Haklai, Ariella Paz, Yoel Kloog
  • Methods and compositions for producing viral particles
    Patent number: 6489142
    Abstract: The invention concerns methods and constructs for producing retroviral particles, in vitro, ex vivo or in vivo. It also concerns the use of said methods and constructs for transferring nucleic acids into cells. More particularly, the invention concerns a composition comprising the whole set of genetic elements required for constituting a retroviral particle, incorporated in one or several recombinant adenoviruses defective for all or part of the regions E1 and E4 at least (adenoviral/retroviral chimeric vectors).
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: December 3, 2002
    Assignees: Aventis Pharma S.A., Genopoietic
    Inventors: Christophe Torrent, Patrice Yeh, Michel Perricaudet, David Klatzmann, Jean-Loup Salzmann
  • Peptides for inhibition of HIV infection
    Patent number: 6489449
    Abstract: The present invention relates to peptides that can inhibit the infection of HIV, and more particularly, to peptides consisting of less than 30 amino acids which can introduce a helix capping motif into a peptide derived from C-terminal helical region (its 628-646th amino acid region) of gp41, an envelope glycoprotein of HIV, as well as consisting of the symmetrical bivalent peptide through the introduction of a branched amino acid, Fmoc-Lys(Fmoc)-OH at C-terminus of its peptide, and induce a more stable helical structure thus inhibiting the infection of HIV.
    Type: Grant
    Filed: April 16, 2001
    Date of Patent: December 3, 2002
    Assignee: Korea Institute of Science and Technology
    Inventors: Yeon Gyu Yu, Key-Sun Kim, Bong-Suk Jin
  • System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
    Patent number: 6485937
    Abstract: Recombinant expression systems for the production of proteins, and particularly a system for rapidly generating recombinant silkworm baculoviruses. Bombyx mori nuclear polyhedrosis virus (BmNPV) with an efficiency approaching 100% has been developed. In a specific example, the vector of the invention was used to generate expression of a FLAG-epitope tagged HIV tat interacting protein of 30 kDa (f-TIP30) in BmN cells and silkworm larvae.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: November 26, 2002
    Assignee: The Rockefeller University
    Inventors: Vikas B. Palhan, Robert G. Roeder
  • Broad spectrum infectious bursal disease virus vaccine
    Patent number: 6485940
    Abstract: The present invention provides a broad spectrum IBDV vaccine that is able to induce a protective immune response against classical- and variant E IBDV strains. Moreover, the vaccine can be administered to poultry by mass application routes.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: November 26, 2002
    Assignee: Akzo Nobel N.V.
    Inventors: Egbert Mundt, Adriaan Antonius Wilhelmus Maria Loon Van
  • Replicating or semi-replicating viral constructs, preparation and uses for gene delivery
    Patent number: 6485965
    Abstract: The invention relates to the use of replicating or semi-replicating viral construct(s) for the preparation of a composition for gene delivery into cells in vivo, ex vivo or in vitro. The invention also relates to novel retroviral constructs, packaging cells and nucleic acids which can be used in methods of delivering polynucleotides to cells.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: November 26, 2002
    Inventors: David Klatzmann, Arnaud Morel, Georg Holzer, Jean-Loup Salzmann
  • Method for inhibiting CD95-independent apoptosis in AIDS
    Patent number: 6485929
    Abstract: The invention relates to a method for inhibiting CD95-independent apoptosis, comprising the following steps: (a) blocking the bonding of HIV-1 gp120 on receptors CD4 and/or CXCR4 or of a factor competing for this bonding, and/or (b) inhibiting the signal path induced by the bonding of (a). The invention also relates to a system for identifying substances which can be utilized for inhibiting CD95-independent apoptosis.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: November 26, 2002
    Assignee: Deutsches Krebsforschungzentrum Stiftung des offentlichen Rechts
    Inventors: Peter Krammer, Christina Berndt
  • Use of bacteriophages for control of escherichia coli O157
    Patent number: 6485902
    Abstract: A method of reducing levels of E. coli O157 strains within the gastrointestinal tract of a ruminant animal using specific bacteriophage(s) is herein described. Also described is a pharmaceutical composition comprising at least one of said bacteriophages and a method for isolating or selecting bacteriophages useful in reducing E. coli O157 levels as described above.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: November 26, 2002
    Inventors: Thomas E. Waddell, Amanda Mazzocco, Jennifer Pacan, Rafig Ahmed, Roger Johnson, Cornelius Poppe, Rasik Khakhria
  • Vitamin B12 —biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
    Patent number: 6482413
    Abstract: The invention relates to a novel complex for oral delivery of drugs, therapeutic protein/peptides and vaccines which are loaded in a Vitamin B12 (VB12) coupled particulate carrier system with spacers in between, the carrier system with spacers having a formula VB12—R′/R″—N wherein, R′ or R″ is spacer and/or agents for derivatization of VB12 to provide either NH2 or COOH or SH groups, and N is the micro or nano particle carriers for the delivery of injectable drugs, therapeutic protein/peptides and vaccines.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: November 19, 2002
    Assignee: Council of Scientific and Industrial Research
    Inventors: Kishore Babu Chalasani, Vamanrao Diwan, Kondapuram Vijaya Raghavan, Gregory John Russell-Jones, Sanjain Kumar Jain, Kollipara Koteshawar Rao
  • Polypeptide having human HIV inhibitory activity, a gene encoding the polypeptide, a method to produce the polypeptide
    Patent number: 6482412
    Abstract: A novel compound, which is effective for treatment of AIDS and has inhibitory activity on human immunodeficiency viruses (HIV), was examined. The K97-0003 peptide, which has anti-HIV activity caused by inhibition of syncytium formation by fusion of envelope glycoprotein of HIV and the host cells expressing the receptor to said virus, was provided by the present invention. Furthermore, the base sequence of the gene coding for said polypeptide, and the method for preparing said polypeptide using strain K97-0003 were provided.
    Type: Grant
    Filed: January 24, 2001
    Date of Patent: November 19, 2002
    Assignees: Gakkou Houjin Kitasato Gakuen, Japan Society for the Promotion of Science
    Inventors: Haruo Tanaka, Satoshi Ohmura
  • Stress proteins and uses therefor
    Patent number: 6482614
    Abstract: The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results in a decrease of an individual's immune response to his or her own cells. The present invention also relates to compositions comprising a stress protein joined to another component, such as a fusion protein in which a stress protein is fused to an antigen. Further, the present invention relates to a method of generating antibodies to a substance using a conjugate comprised of a stress protein joined to the substance.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: November 19, 2002
    Assignee: Whitehead Institute for Biomedical Research
    Inventor: Richard A. Young
  • Humanized antibody and uses thereof
    Patent number: 6479284
    Abstract: A humanized antibody framework motif is described. Preferably, the motif is encoded by the VH gene of K5B8 and the VL gene of TR1.6. This humanized antibody preferably contains the variable region of a tat antibody.
    Type: Grant
    Filed: September 12, 2000
    Date of Patent: November 12, 2002
    Assignees: Dana-Farber Cancer Institute, Inc., Avant Immunotherapeutics, Inc., Chiron Corporation
    Inventors: Wayne A. Marasco, Joyce Lavecchio, Abner Mhashilkar, Urban Ramstedt, David Ring, Bridget Eberhardt, Julie Porter-Brooks
  • Maize histone deacetylases and their use
    Patent number: 6479629
    Abstract: Histone deacetylases and nucleotide sequences encoding said histone deacetylases are provided. The sequences as well as corresponding antisense constructs are useful for modulating gene activity in plants. Additionally, the sequences are useful for enhancing disease resistance in transformed plants.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: November 12, 2002
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Donald Adelphi Baldwin, Steven P. Briggs, Virginia C. Crane